Sci Rep
Oral vs. transdermal menopausal hormone therapy: What's the effect on NAFLD?
Findings indicate that transdermal estrogen is more beneficial than oral estrogen in terms of preventing the progression or development of NAFLD in postmenopausal women.
- This study included 368 postmenopausal women who received MHT for one year. Based on the route of estrogen, patients were divided into transdermal (n = 75) and oral (n = 293) groups.
- After MHT, NAFLD prevalence decreased from 24% to 17.3% in the transdermal group but increased from 25.3% to 29.4% in the oral group.
- Changes in the prevalence of NAFLD weren't significantly different based on the dose of estrogen or type of progestogen.
Source:
Kim S.E., et al. (2023, September 19). Sci Rep. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509271/